BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E. Cohen, a member of its Board of Directors, passed away on Thursday, November 22, 2012 at the age of 76. Mr. Cohen has been a valued member of the Board of Directors and was a member of several committees, including the Audit Committee. Mr. Cohen had a long career in the pharmaceutical industry, where he played a key role in the development of international business for Merck & Co. While at Merck, Mr. Cohen was a leader in the development of Merck’s international business, initially in Asia, then in Europe and, subsequently, in all international regions as President of Merck Sharp & Dohme, which manufactures and markets human health products outside the United States. “It was a great privilege to work with a man of Barry’s stature,” said Michael D. West, CEO of BioTime. “His enthusiasm and energy for the industry was infectious. We will continue to labor to advance his vision of a brighter future for mankind through advances in medical research.”
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.